1)  Rosiglitazone
固醇调节元件结合蛋白1c
1.
Study on Fatty Liver Disease of Macroangiopathy in Rat Model of Type 2 Diabetes Mellitus and the Effect of Rosiglitazone Interence;
NAFLD的确切发病机制尚未完全阐明,其中以固醇调节元件结合蛋白1c(SREBP-1c)及过氧化物酶体增值物激活受体γ辅激活因子1α(PGC-1α)为调控中心的糖、脂代谢紊乱,胰岛素抵抗等在NAFLD的发生发展过程中可能起着重要作用。
2)  Sterol regulatory element binding protein-1c
固醇调节元件结合蛋白-1c
1.
Sterol regulatory element binding protein-1c and hepatic steatosis;
固醇调节元件结合蛋白-1c与肝脂肪变性
3)  sterol regulatory element binding proteins-1c
固醇调节元件结合蛋白-1c
1.
Objective To investigate the expression of sterol regulatory element binding proteins-1c(SREBP-1c)in the liver tissues during fatty diet-induced non-alcoholic steatohepatitis(NASH) in rats and to explore the relationship between the expression of SREBP-1c and nonalcoholic steatohepatitis.
目的观察高脂饮食诱导大鼠非酒精性脂肪性肝炎(NASH)过程中肝组织固醇调节元件结合蛋白-1c(SREBP-1c)的表达变化,探讨SREBP-1c与NASH的关系。
2.
Objective To explore the relationship between the 54G/C single nucleotide polymorphism of exon 18c of sterol regulatory element binding proteins-1c and type 2 diabetes mellitus in Chinese Han population from Hubei province.
目的探讨中国湖北地区汉族人群固醇调节元件结合蛋白-1c(SREBP-1c)基因外显子18c 54G／ C单核苷酸多态性(single nucleotide polymorphism,SNP)与2型糖尿病之间的关系。
4)  SREBP-1c
固醇调节元件结合蛋白-1c
1.
Advanced Research of SREBP-1c Transcriptional Regulation in Fatty Liver Formation;
固醇调节元件结合蛋白-1c在肝脂肪合成中转录调节
2.
Objective:To study the effect of TNF-α(Tumor Necrosis Factor-α) on the expression of Sterol Regulatory Element Binding Protein(SREBP) Cleavage-Activating Protein (SCAP) and SREBP-1c in a model of hepatocyte steatosis,so as to explore the role and possible mechanism by which TNF-αacts on the SCAP-SREBP-1c pathway of lipid synthesis in nonalcoholic fatty liver disease(NAFLD).
目的:通过本研究探讨TNF-α对肝细胞脂肪变性模型固醇调节元件结合蛋白裂解激活蛋白(SCAP)及固醇调节元件结合蛋白-1c(SREBP-1c)表达的影响,探讨TNF-α在非酒精性脂肪性肝病(NAFLD)SCAP-SREBP-1c脂质合成通路中的作用及可能机制。
5)  SREBP-1c
固醇调节元件结合蛋白-1c（SREBP-1c）
6)  Sterol regulatory element binding protein-1c of the liver
肝固醇调节元件结合蛋白-1c
补充资料：麦固醇 ,谷固醇
药物名称：谷固醇

英文名：Sitosterol

别名： β-谷固醇;谷甾醇;麦固醇 ,谷固醇
外文名：Sitosterol
适应症： 用于Ⅱ型高脂血症及预防动脉粥样硬化。
用量用法： 口服：每次服混悬剂２０～３０ｍｌ，每日３次，饭前或饭后即服。
注意事项： 大剂量时可出现食欲减退、胃肠道痉挛、腹泻等。
规格： 混悬剂：２０％。


类别：调节血脂及抗动脉硬化药
说明：补充资料仅用于学习参考，请勿用于其它任何用途。